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series of AOSD. We assessed the efficacy of ANK in a series of
AOSD patients.
Multicenter retrospective open-label study. ANK was used due to
lack of efficacy to standard synthetic immunosuppressive drugs and in
some cases also to at least 1 biologic agent.
Forty-one patients (26 women/15 men) were recruited. They had a
mean age of 34.4 14 years and a median [interquartile range (IQR)]
AOSD duration of 3.5 [2–6] years before ANK onset. At that time the
most common clinical features were joint manifestations 87.8%, fever
78%, and cutaneous rash 58.5%. ANK yielded rapid and maintained
clinical and laboratory improvement. After 1 year of therapy, the
frequency of joint and cutaneous manifestations had decreased to
41.5% and to 7.3% respectively, fever from 78% to 14.6%, anemia
from 56.1% to 9.8%, and lymphadenopathy from 26.8% to 4.9%. A
dramatic improvement of laboratory parameters was also achieved. The
median [IQR] prednisone dose was also reduced from 20 [11.3–47.5]
mg/day at ANK onset to 5 [0–10] at 12 months. After a median [IQR]
follow-up of 16 [5–50] months, the most important side effects were
cutaneous manifestations (n¼ 8), mild leukopenia (n¼ 3), myopathy
(n¼ 1), and infections (n¼ 5).
ANK is associated with rapid and maintained clinical and laboratory
improvement, even in nonresponders to other biologic agents. However,
joint manifestations are more refractory than the systemic manifestations.
(Medicine 94(39):e1554)
Abbreviations: ACR = American College of Rheumatology, ANK
= anakinra, AOSD = adult-onset still disease, CRP = c-reactive
protein, DMARD = disease-modifying antirheumatic drugs, ESR =
erythrocyte sedimentation rate, FDA = Food and Drug
Administration, IFN-g = interferon-g, IL-1 = interleukin 1, IL-6
= interleukin-6, IL-18 = interleukin 18, IQR = interquartile range,
NSAIDS = non-steroidal anti-inflammatory drugs, SD = standarddeviation, TNF-a = tumor necrosis factor-a.
A dult-Onset Still’s Disease (AOSD) is a systemic inflam-matory disease of unknown origin characterized by daily
high-spiking fevers, evanescent maculopapular rash, sore
throat, arthritis and/or arthralgia, myalgia, serositis, lymphade-
nopathy, and hepatosplenomegaly. Laboratory evaluation typi-ated acute-phase reactants, leukocytosis
inance, elevated levels of liver enzymes,
m ferritin.1,2
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AOSD is considered a complex autoinflammatory syn-
drome in which various environmental factors trigger an auto-
inflammatory systemic response in genetically predisposed
individuals. Interleukin-1 (IL-1) appears to be implicated in
AOSD pathogenesis as increased levels of this cytokine have
been found in these patients compared to healthy controls.3,4
Cytokine profile in AOSD sera is also characterized by the
presence of interleukin-6 (IL-6), IL-18, tumor necrosis factor-a
(TNF-a), and interferon-g (IFN-g).5,6 Moreover, one of the
major events in the pathogenesis of this syndrome seems to be a
dysregulation of inflammasome complex and a related over-
production of active IL-1b promoted by IL-18.7
The central role of the inflammasome complex may
explain the intermittent course of the disease and the clinical
and laboratory features that are found in genetically predisposed
autoinflammatory syndromes.
First-line treatment in AOSD has been classically based on
nonsteroidal anti-inflammatory drugs (NSAIDs) and corticoster-
oids. In an attempt to use the lowest possible dose of corticoster-
oids, other therapies, such as methotrexate, azathioprine,
leflunomide, intravenous immunoglobulin, anti-TNF-a drugs,
rituximab, or abatacept, are often given to achieve adequate
control of the disease. However, the efficacy of these drugs is
variable and they are not exempt from potential severe side effects.
Anakinra (ANK) is a recombinant, nonglycosylated form
of human IL-1 receptor that acts as a pure receptor antagonist
binding tightly to the IL-1 receptor and preventing activation of
this receptor by either IL-1b or IL-1a. Approved by the Food
and Drug Administration (FDA) for the treatment of rheumatoid
arthritis in 2001, its use in AOSD is supported by the pivotal role
of IL-1b in this disease. In fact, ANK has been used for the
treatment of AOSD with satisfactory results. However, in most
cases information related to this issue was based on isolated
cases reports or AOSD small series.3,4,8–11
Nevertheless, in an open, randomized, multicenter study
that included 22 patients with AOSD taking prednisolone
10 mg/day, ANK induced more beneficial responses than
disease-modifying antirheumatic drugs (DMARD).12
Taking into account these considerations, our aim was to
evaluate the efficacy of ANK in a large series of Spanish
patients with AOSD refractory to other therapies.
METHODS
Patients and Study Protocol
We conducted a retrospective, open-label, multicenter
study that included 41 patients with AOSD. All patients had
previously received standard synthetic immunosuppressive
drugs and in some case other biologic agents. ANK was given
due to lack of efficacy and/or adverse events to these drugs.
AOSD was diagnosed at the Rheumatology units of 19 Spanish
referral centers according to Yamaguchi’s criteria.13
Before ANK onset, infections including hepatitis B or
hepatitis C infections were excluded. In all patients latent
tuberculosis was also ruled out by a tuberculin skin testing
(PPD) and/or quantiferon and chest radiograph. Analysis of
results was performed based on the information registered by
each investigator following a protocol agreed beforehand that
included the collection of the relevant clinical and laboratory
data of the patients. This was an observational study of ANK
therapy in patients with refractory AOSD. In studies such as
Ortiz-Sanjuán et althis, ethics committee approval is not mandatory according to
Spanish national regulation. However, written informed consent
is mandatory and was obtained from all patients.
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The medical records were reviewed according to a pre-
viously established protocol. According to that, fever was
defined if the temperature was 388C in the week before
the assessment period. Joint symptoms included arthralgia
and/or arthritis. Cutaneous rash was considered to be present
if patients had a salmon-pink, macular, or maculopapular rash
predominantly on trunk and extremities. Hepatomegaly and
splenomegaly if enlargement of liver or spleen was confirmed
by ultrasound or computed tomography. Lymphadenopathy
was defined as the enlargement of lymph nodes in at least 2
different sites. A diagnosis of pericarditis was made if the
patient presented with chest pain and had pericardial rub or an
effusion documented by echocardiogram. Pleuritis was ident-
ified by the presence of pleuritic pain and pleural effusion.
Improvement of the clinical manifestations was considered to
be present if resolution of the clinical manifestations occurred
during the follow-up period.
Laboratory Data
According to the study protocol, information on routine
laboratory markers of disease activity, including full blood cell
count, erythrocyte sedimentation rate (ESR), C-reactive protein
(CRP), ferritin serum levels, liver enzymes, creatinine serum
level, proteinuria, and hematuria was collected.
Anemia was defined as a hemoglobin level 11 g/dL.
Leukocytosis as a white blood cell count 11,000/mm3. The
ESR was considered to be increased when it was higher than 20
or 25 mm/1st hour for men or women, respectively. CRP was
defined as elevated when it was higher than 0.5 mg/dL. High
ferritin serum level was defined as a serum ferritin200 ng/mL.
Data Collection and Statistical Analysis
Data were first reviewed and then analyzed in an attempt to
assess the following information: clinical and laboratory data,
therapies used in the management of AOSD, including those
given to the patients before the onset of ANK, response to this
biologic therapy and adverse events. This information was
extracted from the patients? clinical records, reviewed for
confirmation of the diagnosis, and stored in a computerized file
according to a protocol established beforehand and agreed
upon by researchers. To minimize entry error all the data were
double-checked.
Statistical analysis was performed using the software
STATISTICA (StatSoft Inc. Tulsa, OK). Results were expressed
as meanSD for variables with a normal distribution or as
median and [25th–75th interquartile range (IQR)] when they
were not normally distributed. The comparison of continuous
variables was performed using the Wilcoxon test.
The effect of ANK on clinical features and other variables
such as leukocyte count and hemoglobin level, ESR, CRP,
ferritin, and daily prednisone dose was reviewed. Comparisons
of these variables were made between baseline and 1st month,
3rd month, 6th month, and 1st year. In addition, clinical and
laboratory data observed at last visit were also assessed.
RESULTS
Data from 41 patients (26 women/15 men) with AOSD that
received ANK therapy were assessed. The mean age of the
patients at the onset of ANK was 34.4 14 years and the
Medicine  Volume 94, Number 39, October 2015median [IQR]) duration of AOSD before ANK onset was 3.5
[2–6] years. Besides corticosteroids and before the onset of
ANK all the patients had received traditional synthetic
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
TABLE 1. Main Features of 41 Patients With Refractory Adult-
Onset Still’s Disease Treated With Anakinra (ANK)
Mean ageSD, yr 34.4 14 (range: 16–66)
Sex, men/women 15/26
Disease duration before ANK,
median [IQR], yr
3.5 [2–6]
Immunosuppressive treatment before ANK, n (%)
[0,1-2]Nonbiologic agents
MTX 32 (78.0)
LFN 7 (17.1)
CsA 4 (9.8)
CPM 2 (4.9)
SZP 1 (2.4)
MMF 1 (2.4)
[0,1-2]Biologic agents
ETN 10 (24.4)
ADA 6 (14.6)
IFX 9 (21.9)
TCZ 1 (2.4)
Concomitant treatment with ANK at baseline, n (%)
Corticosteroids 40 (97.6)
MTX 24 (58.5)
HCQ 1 (2.4)
ANK Dose and Interval of Administration
at Baseline,
n (%)
After 1 Yr,
n (%)
100 mg/day 41 (100) 22 (53.7)
100 mg/48h 0 (0) 3 (7.3)
100 mg/72 h 0 (0) 1 (2.4)
100 mg/2 w 0 (0) 1 (2.4)
ADA¼ adalimumab; ANK¼ anakinra; CPM¼ cyclophosphamide;
CsA¼ cyclosporine A; ETN¼ etanercept; HCQ¼ hydroxychloro-
quine; IFX¼ infliximab; IQR¼ interquartile range; LFN¼ lefluno-
mide; MMF¼mycophenolate mophetil; MTX¼methotrexate;
Anakinra in Refractory Adult-Onset Still’s Diseaseimmunosuppressive drugs and 20 (48.8%) of them other bio-
logic therapies (Table 1).
ANK was prescribed as monotherapy (n¼ 12) or com-
bined with other traditional synthetic immunosuppressive drugs
(n¼ 29), usually with methotrexate (Table 1). The initial ANK
dose was 100 mg/sc. every day (Table 1).
At ANK onset the most frequent clinical features were
joint manifestations (n¼ 36), fever (n¼ 32), cutaneous rash
(n¼ 24), lymphadenopathy (n¼ 11), hepatomegaly (n¼ 11),
splenomegaly (n¼ 11), pericarditis (n¼ 8), and pleuritis
(n¼ 6). Most patients also had abnormality of laboratory
parameters including increase of ESR (n¼ 32) or CRP
(n¼ 37), anemia (n¼ 23), and leukocytosis (n¼ 27)
(Table 2). Nevertheless, most of them experienced improve-
ment of clinical manifestations and laboratory abnormalities
following ANK therapy. This improvement was clinically
evident at month 1. The good response to ANK was maintained
over time (Table 2 and Figure 1).
After 1 year of ANK therapy, the frequency of joint
manifestations decreased from 87.8% at baseline to 41.5% of
the patients, the cutaneous manifestations from 58.5% to 7.3%,
fever from 78% to 14.6%, and lymphadenopathy from 26.8% to
4.9%. Also, the frequency of abnormal elevation of CRP and
ESR decreased from 90.2% at the onset of ANK therapy to
46.3% and from 78% to 22% of the patients, respectively. It was
also the case for the frequency of leukocytosis that decreased
from 65.9% to 14.6%, anemia from 56.1% to 9.8%, and high
ferritin serum levels from 63.4% to 36.6% of the patients
(Table 2). Interestingly, after 1 year of ANK therapy the median
[IQR] dose of prednisone had been reduced from 20 [11.3–
47.5] mg/day at the onset of ANK to 5 [0–10] mg/day at 12
months. There was also a significant corticosteroid sparing
effect when basal dose of prednisone was compared with those
taken at 1 month (P< 0.01), at 3 months (P< 0.01), at 6 months
(P< 0.01), and at 12 months (P< 0.01), respectively (Figure 1).
After 1 year from the onset of ANK therapy, 14 patients
(34%) had discontinued this biologic agent because of remis-
sion (n¼ 1), side effects (n¼ 5), lack of efficacy (n¼ 7) and
desire to become pregnant (n¼ 1).
After a median [IQR] follow-up of 16 [5–50] months,
cutaneous reactions were the most common complications
related to ANK therapy (n¼ 8; 19.5%). Nevertheless, in only
2 of these 8 patients the therapy had to be permanently
discontinued due to a severe cutaneous rash. Clinical improve-
ment of the cutaneous rash occurred in both patients following
ANK discontinuation. The remaining 6 patients experienced
mild local cutaneous reactions in the site of ANK injection
(n¼ 6; 14.6%). In terms of infections, this therapy had to be
permanently discontinued because of severe infections in only 2
patients. One of them had phalanx osteomyelitis and the other a
respiratory tract infection by Pseudomonas Aeruginosa and an
abscess in the gluteal muscle. Full recovery following antibiotic
therapy was achieved in both cases. Other infections attributed
to ANK were urinary tract infection (n¼ 2) and herpes zoster
(n¼ 1). Other side effects observed were mild leukopenia
(n¼ 3) and myopathy with elevation of muscle enzymes in 1
patient who had to discontinue ANK therapy for this reason.
Finally, with regard to the combination of ANK with
conventional immunosuppressive drugs, we observed that
improvement of systemic symptoms and joint manifestations
was more commonly observed in those patients who received
Medicine  Volume 94, Number 39, October 2015combined therapy with methotrexate when compared with those
patients taking ANK alone. However, the difference was not
statistically significant (data not shown).
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.DISCUSSION
In this multicenter observational study, we have observed
that ANK yielded a rapid and maintained clinical and laboratory
improvement, even in patients with AOSD refractory to other
biologic agents.
AOSD is considered an IL-1, IL-6, and IL-18-driven
disease. Recently, the therapeutic paradigm of this disease
has shifted to include more specific biologic response modifiers,
especially in patients corticosteroid-dependent and/or refrac-
tory to traditional immunosuppressors. In this sense, our group
has recently reported promising results by the use of the IL-6
inhibitor-tocilizumab in patients with refractory AOSD.14
The rationale for the use of the anti-IL-1 receptor antagon-
ist ANK in AOSD is based on our understanding of the pivotal
role of IL-1 in this disease.1–7 Regarding the cytokine cascade
in AOSD, IL-18 promotes TNF-a, and IL-1 production via the
nuclear factor-kB pathway and induces IFN-g production by
Th1 lymphocytes. TNF-a also induces IL-1. Overproduction of
SD¼ standard deviation; SZP¼ salazopyrin; TCZ¼ tocilizumab;
h¼ hours; w¼week.IL-1b can explain the main symptoms of AOSD, inducing
fever, leukocytosis, thrombocytosis, acute-phase reactant pro-
duction, and bone resorption.
www.md-journal.com | 3
TABLE 2. Improvement of Clinical Manifestations and Laboratory Parameters Following Anakinra Therapy in 41 Adult-Onset
Still’s Disease Patients Refractory to Previous Immunosuppressive Drugs
Clinical Manifestations, % Basal N¼ 41 Month 1 N¼ 41 Month 3 N¼ 37 Month 6 N¼ 32 Month 12 N¼ 27
Joint manifestations 87.8 48.7 41.5 39 41.5
Fever 78 17.1 12.2 10 14.6
Cutaneous manifestations 58.5 9.8 10 4.9 7.3
Lymphadenopathy 26.8 7.3 4.9 4.9 4.9
Splenomegaly and/or hepatomegaly 31.7 19.5 14.6 12.2 5.6
Pleuritis and/or pericarditis 19.5 7.3 2.4 2.4 2.4
Laboratory parameters
Hemoglobin meanSD, g/dL 10.9 2.1 12.1 2.2 12.7 2.2 12.9 2 13 2
Anemia (%) (56.1) (26.8) (17.1) (12.2) (9.8)
Leukocytes/mm3, meanSD 15120.7 7752.3 8606.6 4515.1 8679.3 4122.8 8246.1 3602.8 8300 3853.4
Leukocytosis (%) (65.9) (19.5) (22) (14.6) (14.6)
CRP median [IQR], mg/dL 8.9 [4.4–14.9] 1.1 [0.2–4.3] 0.7 [0.1–1.9] 0.5 [0.1–1.8] 0.5 [0.1–3]
High CRP (%) (90.2) (51.2) (53.7) (51.2) (46.3)
ESR median [IQR], mm/1st h 60.5 [39–87] 18 [10–44] 15.5 [7–31] 9.5 [5.5–25] 10.5 [4.5–22]
High ESR (%) (78) (29.3) (26.8) (19.5) (22)
Ferritin median [IQR], ng/mL 998 [196–4212] 471.5 [76–980] 138 [54.7–498] 159.5 [47–347] 108.5 [47–264]
(39
¼
Ortiz-Sanjuán et al Medicine  Volume 94, Number 39, October 2015Anakinra, a recombinant form of human IL-1 receptor that
High ferritin serum levels (%) (63.4)
CRP¼C-reactive protein; ESR¼ erythrocyte sedimentation rate; IQRbinds to the IL-1 receptor, has demonstrated efficacy in patients
with rheumatoid arthritis.15 Additionally, randomized placebo-
controlled trials disclosed efficacy of ANK in systemic juvenile
FIGURE 1. Rapid and maintained improvement following anakinra th
count and hemoglobin] or median and interquartile range [all other v
line) and hemoglobin value (grey line). B, C-reactive protein (CRP) (bla
C, Ferritin level. D, Sparing corticosteroid dose effect following anaki
4 | www.md-journal.comidiopathic arthritis, an entity that shows some similarities with
) (39) (36.6) (36.6)
interquartile range; SD¼ standard deviation.AOSD.16
ANK has been used in isolated cases and small case series
of refractory AOSD with promising results1,1,3,4,8–12,17–21
erapy (data expressed as mean and standard deviation [leukocyte
ariables] compared with basal results). A, Leukocyte count (black
ck line), and erythrocyte sedimentation rate (ESR) (grey line) levels.
nra therapy.

P<0.05.
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patients treated with ANK because of refractory AOSD were
reported by Laskari et al (n¼ 25) and Giampietro et al
(n¼ 28).10,11 In our study, we describe information on 41
AOSD patients followed for a median of 16 months. In keeping
with former reports,10,11 all the patients from our series had
received synthetic immunosuppressive agents (Table 1). More-
over, many of them had also been refractory to biologic drugs,
mainly anti-TNF-a agents (Table 1).
Improvement of laboratory parameters was found in most
patients from our series at the time of the first available
assessment of data (at month 1) after the onset of ANK therapy.
Of note, improvement compared with basal results was also
observed at 3, 6, and 12 months. In this regard, the significant
reduction of CRP and ESR was especially remarkable compared
with basal data prior to ANK onset. This finding was in
agreement with former reports that also have described decrease
of these acute phase reactants since the first month after the
onset of ANK treatment.10
Rapid improvement of systemic symptoms, such fever and
cutaneous manifestations, was also observed in our series.
Laskari et al10 also reported clinical and laboratory improve-
ment in 18 of 25 patients (72%) after 1 year of treatment with
ANK. Similar results were shown by Giampietro et al.11 How-
ever, it is well known that joint manifestations in patients with
AOSD may be more refractory than systemic manifestations. In
this regard, Cavalli et al11 found a complete response in 37% of
patients with chronic articular disease treated with ANK and
partial response in 25% (18). It was also the case in our series as
41.5% of patients had persistence of joint involvement after 1
year of ANK therapy. Similar results were described by Giam-
pietro et al.11 Taken together, our data along with those from
previous reports indicate that joint manifestations have less
response to anti-IL1 blockade when compared with other
clinical manifestations of AOSD. Likewise, partial improve-
ment of joint manifestations was observed in refractory AOSD
treated with anti-IL-6.14 Nevertheless, Laskari et al10 reported
improvement of joint manifestations (evaluated by ACR50 and
ACR70 response) in 93% and 87% of their patients respectively.
Taken together, the reasons why articular symptoms show
less response to anti-IL-1 therapy when compared with other
organs are unknown. A plausible explanation is that proinflam-
matory cytokines may play a major role in the development of
systemic manifestations of AOSD. According to that, either
anti-IL-1 or anti-IL6 blockade would be more effective to
improve active forms of systemic manifestations of AOSD.
In contrast, joint involvement could be due to a different
pathogenic mechanism, similar to that observed in chronic
inflammatory arthritis, which would explain the partial response
to the biologic agents targeting proinflammatory cytokines.
First-line therapy in AOSD is based on corticosteroids,
often requiring high dose and for a long time with subsequent
risk of side effects. In our series, ANK allowed a significant
corticosteroid sparing effect. Prednisone dose was reduced
significantly following ANK therapy (Figure 1). This is of
particular relevance in patients with chronic course of AOSD,
and in those who are refractory to conventional drugs since
these patients receive an inappropriately high cumulative dose
of corticosteroids leading to a high risk of side effects. This
steroid-sparing effect is also another argument in favor of
recommending ANK, given as a subcutaneous daily injection.
Anakinra in Refractory Adult-Onset Still’s DiseaseANK was relatively safe in our series. Only 5 patients had
to discontinue the treatment due to severe cutaneous reactions,
severe infections and myopathy as described above. Another
www.md-journal.com | 7
minor side effect was mild leukopenia that was transient not
requiring ANK discontinuation. These data were consistent
with previously published series.10,11,19
As described in our study (Table 1), reduction of ANK
dose because of clinical improvement was also performed in
some patients reported by Laskari et al10 and Giampietro et al.11
However, a question still unanswered is the optimal duration of
treatment with ANK in AOSD. In our series, two-thirds of the
patients completed almost 1 year of ANK therapy. Twenty-two
of 41 patients were still receiving a dose of 100 mg/day at 1
year. This biologic therapy had been discontinued in 1 patient
because of clinical remission and a reduction in the number of
doses was achieved in 5 patients in the first year from the onset
of this drug (Table 1). None of these 6 patients experienced
relapses during the extended follow-up. These results were
consistent with those from previous series.10,11 According to
these findings, dose reduction may be considered when remis-
sion is achieved, increasing compliance and drug adherence and
highlighting the potential cost-effectiveness of ANK.
We previously reported good results following anti-IL-6
tocilizumab therapy in AOSD patients refractory to conven-
tional immunosuppressive drugs.14 Therefore, comparison
between ANK and tocilizumab should be conducted.
In conclusion, in the present report, we describe the largest
series of AOSD ANK-treated patients refractory to convention-
al immunosuppressive drugs and in some cases to other biologic
therapies. ANK yielded rapid and maintained clinical and
laboratory improvement in these patients. Although ANK
showed global efficacy, joint manifestations were found to
be more refractory than systemic manifestations. However,
the retrospective and open-label nature of the study constitutes
a potential limitation. Hence, these promising results support
the need for randomized clinical trials on the effectiveness of
IL-1 receptor blockade in AOSD.
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